Biologicals

Plant vaccines

Vaccines are effective means of reducing the disease burden of infectious diseases in developing countries. To ensure the widest availability of these vaccines in poor countries, approaches are needed with lower production costs and less need of medical personnel to administer the vaccines. A promising avenue is the development of plant-derived vaccines, which can be administered orally or to other mucosal surfaces. Plants are able to produce different classes of proteins of pharmaceutical significance at a high yield, leading to potentially inexpensive products. Oral administration is important as it diminishes the need for needles and syringes which require highly trained immunization staff.


RELATED LINKS

ESSENTIAL MEDICINES AND HEALTH PRODUCTS



UPCOMING EVENTS


  • WHO working group meeting on RSV vaccine standardization and clinical evaluation, Geneva, Switzerland, 3-5 February 2016
  • TCV Workshop, NIBSC, Potters Bar, UK, 8-10 March 2016
  • WHO informal consultation on labelling information on influenza vaccines intended to be used for pregnant women, Geneva, Switzerland, 4-5 April 2016
  • WHO informal consultation on WHO guidelines on regulatory preparedness for vaccine non-producing countries in response to pandemic influenza emergency, Geneva, Switzerland, 6-7 April 2016
  • WHO working group meeting on guidelines on the quality, safety and efficacy of Ebola vaccines, Geneva, Switzerland, 4-5 May 2016

Contacts


Technologies Standards and Norms (TSN)
Essential Medicines and Health Products (EMP)
World Health Organization (WHO)
Avenue Appia 20
1211 Geneva 27, Switzerland
Fax No. +41 22 7914971